September 23, 1999 15:40
Steroidogenesis Inhibitors International is Now a Reporting Company
LAS VEGAS--(BW HealthWire)--Sept. 23, 1999--Dr. Alfred T. Sapse, President of Steroidogenesis Inhibitors International (OTC BB: STGI), announced today that on September 19, 1999, the Company became a reporting company upon the effectiveness of its registration statement on Form 10-SB filed with the United States Securities and Exchange Commission for the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934.
Dr. Sapse noted that despite the effectiveness of its registration statement, the Company still has the task of responding to SEC staff comments on the registration statement. The Company intends to respond by September 30, 1999.
STGI is a pharmaceutical company engaged in the field of developing anti-cortisol drugs intended for the treatment of diseases associated with elevated levels of cortisol, aging, cancers, and Alzheimer's included.
This release may include forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For more information visit our World Wide Web page at anticort.com.
CONTACT: Steroidogenesis
Janet Greeson, Ph.D., 702/221-0409
or
Performance Strategies, Inc.
Richard L. Brown/Charles E.(Chuck) Jordan, Sr.
303/948-3601
|
